Comparing the current results to its competitors, Entera Bio Ltd reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.35 %, recorded in the same quarter.
September 25, 2024
Emerging Innovations in Obesity Treatment: Entera Bio and OPKO Health Announce Promising PK/PD Data for Oral Oxyntomodulin Tablet In a novel collaboration, Entera Bio Ltd. (NASDAQ: ENTX) and OPKO Health, Inc. (NASDAQ: OPK) have revealed encouraging topline pharmacokinetic (PK) and pharmacodynamic (PD) outcomes for their oral oxyntomodulin (OXM) tablet candidate. This innovative therapeutic approach leverages OPKO s proprietary OXM analog and Entera’s N-Tab delivery technology, marking a significant step forward in the quest for efficacious oral treatments for obesity, metabolic disorders, and fibrotic diseases. This article delves into the significant strides made in the development of this groundbreaking...
August 9, 2024
Entera Bio Ltd. Reports Q2 2024 Financial Results and Notable Business Updates Entera Bio Ltd. (NASDAQ: ENTX), a frontrunner in the development of orally delivered peptides and small therapeutic proteins, has recently released its financial results for the second quarter of 2024. Additionally, the company has achieved critical milestones in the development of its lead clinical compound, EB613, for the treatment of osteoporosis and low bone mineral density (BMD) in post-menopausal women. This article briefly summarizes Entera Bio s financial performance, key business updates, and exciting advancements in its clinical programs. Financial PerformanceFor the quarter ended June 30, 2024, Entera Bio reported a so...
May 13, 2024
Entera Bio Ltd., a renowned pioneer in the research and development of orally delivered peptides and minor therapeutic proteins, has recently announced that it will present the promising data from the Phase 1 study of PTH(1-34) Peptide Tablets (EB612) an innovative first-in-class treatment for hypoparathyroidism at the prestigious Endocrine Society s Annual Meeting, ENDO 2024. The event, which draws a significant number of experts and researchers from the world of endocrinology, will take place from June 1-4, 2024 in Boston, Massachusetts.Entera Bio s EB612 is the first orally administered, synthetic human parathyroid hormone fragment (1-34) designed for the treatment of hypoparathyroidism, a condition c...
March 26, 2024
In a significant development for the field of osteoporosis treatment, Entera Bio Ltd. has announced a key regulatory milestone for its oral PTH(1-34) peptide (EB613) Phase 3 program. The American Society for Bone and Mineral Research (ASBMR) revealed that the U.S. Food and Drug Administration (FDA) has communicated its intention to rule on the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs. The FDA s decision is expected to be provided within the next 10 months.The Significance of a Surrogate Endpoint for Osteoporosis Drugs:Osteoporosis is a major public health concern, affecting millions of individuals worldwide. T...
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.
Sources:
Entera Bio Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Entera Bio Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
